


CLINICAL TRIAL

CIL 34546-NSR-REP-01
NCT01461213

Retinal RED



Gene therapy study on choroideremia : to assess the safety and tolerability of the AAV.REP1 vector, administered at two different doses to the retina in patients with a diagnosis of choroideremia.

Rare Eye Disease concerned by the trial :
Choroideremia

Status of the trial : completed
Orphan drug recognition : Yes

Inclusion criteria : Visual Acuity between 20/200 and 20/40

Exclusion criteria : age < 18 years



Inclusion
opening date : 01/06/2017



Inclusion closing
date (previsional) : 31/08/2018

Children



Adults



Within ERN-EYE members



Principal location of the trial :

Maolya - National Rare Disease center
Centre national de référence affections
sensorielles génétiques
CHU Gui de Chauliac
80, avenue Augustin Fliche
34 295 Montpellier Cedex 5

[Contact details](#)




Principal investigator name :
Isabelle Meunier



Other investigators :

Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom, EC1V 2PD

St Mary's Hospital, Central Manchester University
Hospitals NHS Foundation Trust
Manchester, United Kingdom, M13 9WL



Funder type : Drug company - Industry

[More informations](#)